NO940874L - 5-HT4 reseptor-antagonister - Google Patents

5-HT4 reseptor-antagonister

Info

Publication number
NO940874L
NO940874L NO940874A NO940874A NO940874L NO 940874 L NO940874 L NO 940874L NO 940874 A NO940874 A NO 940874A NO 940874 A NO940874 A NO 940874A NO 940874 L NO940874 L NO 940874L
Authority
NO
Norway
Prior art keywords
pct
image
sec
formula
receptor antagonists
Prior art date
Application number
NO940874A
Other languages
English (en)
Other versions
NO940874D0 (no
Inventor
Francis David King
Laramie Mary Gaster
Keith Raymond Mulholland
Shirely Katherine Rahman
Paul Adrian Wyman
Gareth John Sanger
Kay Alison Wardle
Gordon Smith Baxter
Guy Anthony Kennett
Alberto Julio Kaumann
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919119449A external-priority patent/GB9119449D0/en
Priority claimed from GB919119692A external-priority patent/GB9119692D0/en
Priority claimed from GB919122474A external-priority patent/GB9122474D0/en
Priority claimed from GB919122473A external-priority patent/GB9122473D0/en
Priority claimed from GB919122624A external-priority patent/GB9122624D0/en
Priority claimed from GB929201414A external-priority patent/GB9201414D0/en
Priority claimed from GB929201413A external-priority patent/GB9201413D0/en
Priority claimed from GB929202510A external-priority patent/GB9202510D0/en
Priority claimed from GB929214399A external-priority patent/GB9214399D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO940874L publication Critical patent/NO940874L/no
Publication of NO940874D0 publication Critical patent/NO940874D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anvendelse av en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav, hvori ^-(CH2)X-X2 danner en 5 til 7-leddet ring hvori; Xx er O eller S; X2 er O, S, NR eller NRCO, hvori R er hydrogen eller C^alkyl; x er l, 2 eller 3; Y er O eller NH; Z er under-formelen (a), (b) eller (c) til fremstilling av et medikament for anvendelse ved behandling av mage-tarm-forstyrrelser, kardiovaskulære for- styrrelser og CNS-forstyrrelser.
NO940874A 1991-09-12 1994-03-11 5-HT4 reseptor-antagonister NO940874D0 (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB919119449A GB9119449D0 (en) 1991-09-12 1991-09-12 Pharmaceuticals
GB919119692A GB9119692D0 (en) 1991-09-14 1991-09-14 Pharmaceuticals
GB919122474A GB9122474D0 (en) 1991-10-23 1991-10-23 Novel compounds
GB919122473A GB9122473D0 (en) 1991-10-23 1991-10-23 Medicaments
GB919122624A GB9122624D0 (en) 1991-10-24 1991-10-24 Pharmaceuticals
GB929201414A GB9201414D0 (en) 1992-01-23 1992-01-23 Medicaments
GB929201413A GB9201413D0 (en) 1992-01-23 1992-01-23 Novel compounds
GB929202510A GB9202510D0 (en) 1992-02-06 1992-02-06 Pharmaceuticals
GB929214399A GB9214399D0 (en) 1992-07-07 1992-07-07 Pharmaceuticals

Publications (2)

Publication Number Publication Date
NO940874L true NO940874L (no) 1994-03-11
NO940874D0 NO940874D0 (no) 1994-03-11

Family

ID=27576345

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940874A NO940874D0 (no) 1991-09-12 1994-03-11 5-HT4 reseptor-antagonister

Country Status (19)

Country Link
US (1) US5580885A (no)
EP (1) EP0604494B1 (no)
JP (1) JP3294611B2 (no)
AT (1) ATE182591T1 (no)
AU (1) AU691430B2 (no)
BR (1) BR9206599A (no)
CA (1) CA2118812C (no)
CZ (1) CZ283619B6 (no)
DE (1) DE69229674T2 (no)
DK (1) DK0604494T3 (no)
ES (1) ES2135414T3 (no)
FI (1) FI941178A0 (no)
GR (1) GR3031462T3 (no)
HU (1) HUT70154A (no)
NO (1) NO940874D0 (no)
NZ (1) NZ244282A (no)
SG (1) SG49153A1 (no)
SK (1) SK30294A3 (no)
WO (1) WO1993005038A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128172A1 (en) 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5763459A (en) * 1992-05-23 1998-06-09 Smithkline Beecham P.L.C. Medicaments for the treatment of anxiety
AU4350493A (en) * 1992-06-27 1994-01-24 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
MX9306311A (es) * 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
US5726187A (en) * 1992-10-16 1998-03-10 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
GR1002176B (en) * 1992-10-19 1996-03-07 Smithkline Beecham Plc Pharmaceutical substances.
EP0667867A1 (en) * 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
GB9312348D0 (en) * 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
WO1996022280A1 (de) * 1995-01-18 1996-07-25 Bayer Aktiengesellschaft N-substituierte-1-acylaminoalkyl piperidine zur behandlung von cerebralen störungen und depressionen
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
DE69602970T2 (de) * 1995-11-09 2000-01-20 Sanofi-Synthelabo, Paris 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol-2(3h)-on-derivate verwendbar als 5-ht4- oder h3-rezeptorliganden
US6096761A (en) * 1996-02-15 2000-08-01 Janssen Pharmaceutica N.V. Esters of 3-hydroxy-piperidinemethanol derivatives
NZ330263A (en) * 1996-02-15 1999-06-29 Janssen Pharmaceutica Nv Esters of 3-hydroxy-piperidinemethanol derivatives to improve gastric emptying
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
AU3784997A (en) * 1996-08-09 1998-03-06 Eisai Co. Ltd. Benzopiperidine derivatives
GB9618967D0 (en) 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals
FR2759699B1 (fr) * 1997-02-20 1999-03-19 Synthelabo Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
DE69935600T2 (de) 1998-09-10 2007-12-06 F. Hoffmann-La Roche Ag Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
MXPA03001210A (es) * 2000-08-07 2004-08-12 Smithkline Beecham Corp Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
KR100545780B1 (ko) * 2003-05-28 2006-01-24 동부한농화학 주식회사 벤즈이미다졸 유도체로 치환된 벤조피란 유도체 또는약학적으로 허용되는 그의 염, 이의 제조 방법 및 이를포함하는 약학적 조성물
KR100512486B1 (ko) * 2003-05-28 2005-09-06 동부한농화학 주식회사 싸이옥소벤즈옥사졸 유도체로 치환된 벤조피란 유도체또는 약학적으로 허용되는 염, 이의 제조방법 및 이를포함하는 약학적 조성물
JP4767844B2 (ja) 2003-06-19 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５ｈｔ４−アンタゴニストとしての複素環式置換４−（アミノメチル）−ピペリジンベンズアミド
ITMI20031468A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco ativo nel dolore neuropatico
JP2009536954A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｅｔｐ阻害剤としての３，４−ジヒドロ−２ｈ−ベンゾ［１，４］オキサジンおよびチアジン誘導体
US7928238B2 (en) 2006-05-11 2011-04-19 Janssen Pharmaceutica Nv 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2509155A1 (de) * 1975-03-03 1976-09-09 Hoechst Ag 1,4-benzoxazinderivate und verfahren zu ihrer herstellung
US4268512A (en) * 1976-08-04 1981-05-19 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation
US4186135A (en) * 1976-08-04 1980-01-29 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation
FR2396757A2 (fr) * 1977-07-08 1979-02-02 Ile De France Nouveaux 2,3-alkylene bis (oxy) benzamides substitues, leurs derives et leurs procedes de preparation
EP0036269A1 (en) * 1980-03-15 1981-09-23 Beecham Group Plc Substituted benzamides
EP0067615B1 (en) * 1981-06-17 1986-01-08 Beecham Group Plc Alkylthio derivatives of azabicyclobenzamides, their preparation and pharmaceutical compositions
SE8503055D0 (sv) * 1985-06-19 1985-06-19 Astra Laekemedel Ab Piperonylcarboxamido derivatives
US4772459A (en) * 1986-09-09 1988-09-20 Erbamont, Inc. Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
EP0385044A1 (en) * 1989-02-28 1990-09-05 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New piperidine derivatives as antihistaminics
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
ATE137501T1 (de) * 1989-07-03 1996-05-15 Yoshitomi Pharmaceutical Benzazin-verbindungen und deren pharmazeutische verwendungen
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
IE912759A1 (en) * 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
WO1992010454A1 (en) * 1990-12-04 1992-06-25 Allied-Signal Inc. Partially fluorinated alkanols having a tertiary structure
JPH05194406A (ja) * 1991-11-12 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 新規アミド化合物

Also Published As

Publication number Publication date
JP3294611B2 (ja) 2002-06-24
DK0604494T3 (da) 1999-11-29
AU668102B2 (en) 1996-04-26
NZ244282A (en) 1995-08-28
WO1993005038A1 (en) 1993-03-18
HUT70154A (en) 1995-09-28
DE69229674T2 (de) 2000-04-06
SG49153A1 (en) 1998-05-18
EP0604494A1 (en) 1994-07-06
HU9400734D0 (en) 1994-06-28
NO940874D0 (no) 1994-03-11
AU6073596A (en) 1996-10-03
SK30294A3 (en) 1994-12-07
FI941178A (fi) 1994-03-11
CA2118812A1 (en) 1993-03-18
CZ283619B6 (cs) 1998-05-13
AU691430B2 (en) 1998-05-14
FI941178A0 (fi) 1994-03-11
US5580885A (en) 1996-12-03
CA2118812C (en) 2006-01-17
AU2541892A (en) 1993-04-05
ES2135414T3 (es) 1999-11-01
EP0604494B1 (en) 1999-07-28
JPH06510537A (ja) 1994-11-24
GR3031462T3 (en) 2000-01-31
BR9206599A (pt) 1994-11-08
DE69229674D1 (de) 1999-09-02
CZ56094A3 (en) 1994-07-13
ATE182591T1 (de) 1999-08-15

Similar Documents

Publication Publication Date Title
DE69229674D1 (de) 5-ht4 rezeptor antagonisten
FI942187A (fi) Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
ATE167470T1 (de) Heterocyclische amine zur therapie von asthma und entzündungen der atemwege
IS6275A (is) Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka
JO2321B1 (en) 4-phenyl-pyridine derivatives
FI943948A (fi) Heterosykliset hiilihappojohdannaiset
DE69530081D1 (de) Gastrin- und cck-antagonisten
JO2371B1 (en) 4-phenyl-pyridine derivatives
HU9502064D0 (en) Thiazolidine derivatives, preparation thereof and drugs containing same
ATE435010T1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
AU1070895A (en) Indole-derived arylpiperazines as ligands for 5HT1-like receptors 5HT1B and 5HT1D
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
MX9604368A (es) Antagonistas de receptores de endotelina.
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
DK0664811T3 (da) Gestagent aktive 4-estrener med bro mellem stillingerne 19,11
ES2065238A1 (es) Derivados de benceno condensados con actividad antagonista del receptor 5-ht4, procedimiento para su preparacion, composiciones que los contienen y aplicaciones.
PT100855A (pt) Utilizacao de um composto heterociclico biciclico, em especial um derivado de benzodioxano, para a preparacao de um medicamento